A Pilot Study of Stereotactic Body Radiation Therapy (SBRT) After TEMLA for Stage III and IV (Oligometastatic) Non-Small Cell Lung Cancer

This is a pilot, single center study. Patients with histologically proven, Stage III/IV NSCLC will be eligible. Patients will be stratified by central or peripheral location of the tumor. All patients will receive TEMLA to remove the mediastinal nodes, followed by a single fraction of SBRT delivering 30 Gy to the primary tumor and 10 Gy to the mediastinal lymph node beds (if possible on TEMLA), with or without minimally invasive surgery. Following radiation therapy, chemotherapy, at the discretion of the medical oncologist, may be initiated at any time after 2 weeks.

Study Number: 

I 223812

Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.